Welcome to our dedicated page for Design Therapeutics SEC filings (Ticker: DSGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Design Therapeutics, Inc. filings document the regulatory disclosures of a Nasdaq-listed, clinical-stage biotechnology company developing GeneTAC® small-molecule therapies for serious degenerative genetic diseases. Its 8-K reports furnish financial results, corporate presentations, pipeline updates, and material governance events tied to board appointments, resignations, committee assignments, director compensation, and indemnification arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, stockholder voting procedures, and board structure. The filing record also identifies the company’s common stock registration on The Nasdaq Global Select Market, emerging growth company status, and public-company disclosure framework for operations, capital structure, governance, and risk reporting.
Design Therapeutics director and 10% owner George Simeon received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 8, 2036. They vest in equal monthly installments over 12 months after June 9, 2026, or will be fully vested by the company’s next annual stockholder meeting.
Design Therapeutics, Inc. director John P. Schmid received a grant of stock options covering 30,000 shares of common stock. These options have an exercise price of $10.55 per share and expire on June 8, 2036.
The options vest in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the date of the company’s next annual meeting of stockholders. After this grant, Schmid holds options on 30,000 shares directly.
Design Therapeutics, Inc. director Rodney W. Lappe received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 8, 2036.
According to the disclosure, these options were awarded as compensation and will vest in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the company’s next annual stockholder meeting. Following this grant, Lappe holds derivative securities representing 30,000 underlying shares directly.
Design Therapeutics, Inc. reported that director Justin D. Gover received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 8, 2036. The award vests in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the date of the company’s next annual meeting of stockholders. Following this grant, Gover holds 30,000 stock options directly.
Design Therapeutics, Inc. director David Shapiro received a stock option grant covering 30,000 shares of common stock. The option has an exercise price of $10.55 per share and expires on June 8, 2036. The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the date of the company’s next annual meeting of stockholders. This is a compensation-related award, not an open-market purchase or sale.
Design Therapeutics, Inc. director Heather A. Berger received a grant of stock options covering 30,000 shares of Common Stock at an exercise price of $10.55 per share. These options now represent 30,000 derivative securities held directly after the transaction.
The options vest in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the date of the company’s next annual meeting of stockholders, aligning vesting with ongoing board service.
Design Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of the April 14, 2026 record date, 62,441,429 shares of common stock were outstanding and entitled to vote.
Stockholders elected Simeon George, M.D. as a Class II director, with 29,205,208 votes for, 7,608,724 votes withheld and 13,264,883 broker non-votes. They also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 50,077,708 votes for, 201 votes against and 906 abstentions.
Design Therapeutics, Inc. reports that Point72-related filers beneficially own 3,197,764 shares of common stock, equal to 5.1% of the class, as of the close of business on June 8, 2026. The disclosure is made on a Schedule 13G and identifies shared voting and dispositive power among Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen.
Design Therapeutics reported new biomarker and clinical data from its ongoing Phase 1/2 RESTORE-FA trial of DT-216P2 in Friedreich ataxia. Sixteen patients received weekly intravenous doses from 0.1 to 1 mpk for four weeks.
At the 1 mpk dose, patients showed mean improvements of 6.4 points on the modified Friedreich’s Ataxia Rating Scale and 2.7 points in the Upright Stability Score. Patient-reported fatigue improved by more than five points on the PROMIS Fatigue Scale at four weeks and two weeks after the last dose, exceeding the three-point minimal important change. Whole blood FXN mRNA increased 65%, FXN-M and FXN-E protein rose 22–27%, and muscle FXN mRNA increased 42%, indicating robust frataxin restoration. DT-216P2 was generally well-tolerated, with only mild to moderate adverse events. The company plans to pursue a registrational path and provide an update in the fourth quarter of 2026.
Design Therapeutics ownership disclosure: Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen report 2,722,754 shares of common stock, representing 4.4% of the class as of March 31, 2026. The filing states they hold shared voting and shared dispositive power through investment management arrangements; each Reporting Person directly owns no shares.